Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.55 USD

76.55
859,950

+1.47 (1.96%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $76.58 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Haemonetics (HAE) Autotransfusion System Gets 510(k) Clearance

by Zacks Equity Research

The latest development is expected to upgrade Haemonetics' (HAE) Cell Salvage platform and broaden the company's scope in the growing autotransfusion space.

Neogen's (NEOG) New Launches Aid, Margin Pressure Stays

by Zacks Equity Research

Neogen (NEOG) continues to see rising revenues from the Food Safety business.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the continued strength of GYN Surgical and Breast Health businesses.

Hologic's (HOLX) Strategic Buyouts Aid, Surgical Arm Grows

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical results underscore a more diverse surgical business with more growth drivers than in the past.

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on the growing market adoption of the iTero Element 5D Plus imaging system.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strong global performance.

Medtronic's (MDT) MiniMed 780G System Shows Favorable Results

by Zacks Equity Research

Medtronic's (MDT) MiniMed 780G system was designed to forecast real-life requirements where carbohydrate counts aren't always exact and meal doses are often missed.

Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.

Kevin Cook headshot

Bull of the Day: Haemonetics (HAE)

by Kevin Cook

Leader in blood management for hospitals see estimates and price targets rise after strong quarter

New Strong Buy Stocks for February 10th

by Zacks Equity Research

SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.

Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics

by Zacks Equity Research

Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.

Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 7.59% and 4.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) to Post Q4 Earnings: What You Should Expect

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.

Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.

STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Phibro Animal Health (PAHC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cigna (CI) to Post Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.

Looking for a Growth Stock? 3 Reasons Why Haemonetics (HAE) is a Solid Choice

by Zacks Equity Research

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Haemonetics (HAE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.